Allakos, which is developing antibodies for allergic, inflammatory and proliferative diseases, raised $128 million by offering 7.1 million shares at $18, above the $15 to $17 range. The company originally planned to offer 6.0 million shares. Insiders intended to buy $35 million on the IPO (27% of the deal). Allakos plans to list on the Nasdaq under the symbol ALLK. Goldman Sachs and Jefferies acted as lead managers on the deal.
